Hester Biosciences Limited

BSE: 524669 NSE: HESTERBIO
Hester Biosciences Limited - pharma in Mahesana, Gujarat, India. FY 2026 financials and compliance.
CIN L99999GJ1987PLC022333 Incorporated 29 April 1987 ROC Ahmedabad HQ Mahesana, Gujarat, India
Active Listed - NSE: HESTERBIO · BSE: 524669 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹332.6 Cr
▲ 6.91% YoY
EBITDA · FY 2026
₹96.34 Cr
▲ 48.27% YoY
Net profit · FY 2026
₹57.48 Cr
▲ 99.42% YoY
Authorised capital
₹11.2 Cr
Registered with MCA
Paid-up capital
₹8.51 Cr
Issued & subscribed
Open charges
₹202.05 Cr
Satisfied ₹90.09 Cr
Company age
39 yrs
Est. 1987
Employees · EPFO
695
Latest available

About Hester Biosciences Limited

Data last updated: 28 January 2026

Hester Biosciences Limited is a public limited company based in Mahesana, Gujarat, India. It specialises in animal pharmaceuticals and healthcare, a part of the broader pharmaceuticals sector. Incorporated on 29 April 1987, the company has been in operation for over 39 years.

Registered with ROC Ahmedabad under CIN L99999GJ1987PLC022333. Listed on BSE: 524669 and NSE: HESTERBIO.

Capital: an authorised share capital of ₹11.2 Cr and a paid-up capital of ₹8.51 Cr. Formerly known as Hester Pharmaceuticals Limited and Hester Pharmaceuticals Private Limited. It is led by directors including Jatin Yagneshbhai Trivedi and Sandhya Maulik Patel.

Last AGM: 13 August 2025. Financial statements filed for year ended 31 March 2025. Office: Mahesana, Gujarat.

As per the financials filed for FY 2025, the company reported a revenue of ₹315.03 Cr, a growth of 0% compared to the previous year.

The company has a workforce of approximately 695 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Hester Biosciences. As per MCA filings, the company has open charges of ₹202.05 Cr and satisfied charges of ₹90.09 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hester.in.

Company Details of Hester Biosciences Limited
CIN L99999GJ1987PLC022333
Registration Number 022333
Incorporation Date 29 April 1987
ROC Ahmedabad
Listing Status Listed (BSE: 524669, NSE: HESTERBIO)
Company Status Active
Date of Last AGM 13 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Rajiv Dinesh Gandhi Managing Director Priya Rajiv Gandhi Whole-Time Director Jatin Yagneshbhai Trivedi Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    hester.in
  • Social Media
  • Registered Address
    Village Meda – Adraj, Taluka Kadi, Mahesana, Gujarat, India – 384441
  • Industry
    Pharma, Animal Pharmaceuticals & Healthcare
Company report
Hester Biosciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Hester Biosciences Limited report

Financials, compliance, directors, charges, ownership and filings for Hester Biosciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Hester Biosciences Limited

Hester Biosciences Limited has undergone 2 name changes throughout its history. The company was previously known as Hester Pharmaceuticals Limited, and Hester Pharmaceuticals Private Limited. The current legal name is Hester Biosciences Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Hester Biosciences Limited Current
Hester Pharmaceuticals Limited Previous
Hester Pharmaceuticals Private Limited Previous

CIN History of Hester Biosciences Limited

Hester Biosciences Limited has one previous CIN (Corporate Identification Number): L99999GJ1994PTC022333. The current CIN is L99999GJ1987PLC022333, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L99999GJ1987PLC022333 Current
L99999GJ1994PTC022333 Previous

Associated Brands with Hester Biosciences Limited

Hester Biosciences Limited operates one associated brand: Hester Biosciences. These brands represent Hester Biosciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Hester Biosciences
Manufacturer of animal vaccines and healthcare products hester.in

Competitors & Alternatives of Hester Biosciences Limited

Brands and companies operating in the same space as Hester Biosciences Limited include Zoetis, Ceva, QBiotics and 6 more.

Competitor Description Location Founded
Zoetis Zoetis Animal medicines, vaccines, and diagnostics are manufactured and supplied. Brussels, Belgium, Belgium 2012
Ceva Ceva Animal health therapeutics are developed and supplied globally by Ceva. Libourne, France, France 1999
QBiotics QBiotics Small molecules from plant extracts are developed for medical applications. Brisbane, Australia, Australia 2000
PetMedix PetMedix Developer of monoclonal antibody therapeutics for pets Babraham, United Kingdom, United Kingdom 2017
Bio-Sourcing Bio-Sourcing Biopharmaceuticals for animals are manufactured and supplied through partnerships. Liege, Belgium, Belgium 2014
KindredBio KindredBio Veterinary antibodies for cats, dogs, and horses are developed. Burlingame, United States, United States 2012
The Vaccine Group The Vaccine Group Herpesvirus-based animal vaccines are developed against infectious diseases. Plymouth, United Kingdom, United Kingdom 2017
Bactana Corporation Bactana Corporation Proprietary microbiome technology is developed for companion and food animals. Farmington, United States, United States 2016
Weijiexin Biological Technology Weijiexin Biological Technology Protein-based biopharmaceuticals for animal disease treatment are developed. Haidian, China, China 2016

Business Activity of Hester Biosciences Limited

Hester Biosciences Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********
G Trade G1 Wholesale Trading *********

Auditor Details of Hester Biosciences Limited

Hester Biosciences Limited is audited by Chandulal M. Shah & Co. (ICAI peer reviewed, certificate valid till 2026-06-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Chandulal M. Shah & Co. (ICAI peer reviewed, certificate valid till 2026-06-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Hester Biosciences Limited

Hester Biosciences Limited is currently managed by 13 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Jatin Yagneshbhai Trivedi
Also directs: Hester Biosciences Limited, Y.J. Trivedi Ip Llp, Tie Ahmedabad Association and 3 more
Director 26 Jun 2023 3 Years 0 Months Current
Sandhya Maulik Patel
Also directs: Hester Biosciences Limited, Atvantic Finechem Private Limited, Varmora Granito Limited
Director 01 Apr 2020 6 Years 3 Months Current
Ravin Kanti Gandhi
Also directs: Hester Biosciences Limited
Director 22 Apr 1999 27 Years 2 Months Current
Ameetkumar Hiranyakumar Desai
Also directs: Anubhuti Advisors Llp, Proplus Advisors Llp, Corona Remedies Limited and 5 more
Director 28 Oct 2021 4 Years 8 Months Current
Sanjiv Dinesh Gandhi
Also directs: Hester Biosciences Limited, Biolink Healthcare Limited, Stroke India Help Association and 1 more
Director 29 Apr 1987 39 Years 2 Months Current
Nina Rajiv Gandhi
Also directs: Hester Biosciences Limited, Biolink Healthcare Limited, Hester Diagnostics Private Limited and 3 more
Alternate Director 07 May 2016 10 Years 2 Months Current
Showing 6 of 13 current directors. View all directors

Financials of Hester Biosciences Limited FY 2026 filings available

Hester Biosciences Limited reported revenue of ₹332.6 Cr (up 6.91% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹332.6 Cr ▲ 6.91%
Profit · FY 2026
₹57.48 Cr ▲ 99.42%
EBITDA · FY 2026
₹96.34 Cr ▲ 48.27%
Revenue₹ Cr · Consolidated0200400FY 2020: ₹183 Cr183FY 2020FY 2021: ₹214 Cr · +16.9% YoY214+16.9%FY 2021FY 2022: ₹235 Cr · +9.6% YoY235+9.6%FY 2022FY 2023: ₹266 Cr · +13.2% YoY266+13.2%FY 2023FY 2024: ₹305 Cr · +14.5% YoY305+14.5%FY 2024FY 2025: ₹311 Cr · +2.2% YoY311+2.2%FY 2025FY 2026: ₹333 Cr · +6.9% YoY333+6.9%FY 2026
Net Profit₹ Cr · Consolidated0204060FY 2020: ₹31 Cr31FY 2020FY 2021: ₹35 Cr · +11.9% YoY34.7+11.9%FY 2021FY 2022: ₹39 Cr · +13.8% YoY39.5+13.8%FY 2022FY 2023: ₹28 Cr · -29% YoY28-29%FY 2023FY 2024: ₹21 Cr · -24.5% YoY21.2-24.5%FY 2024FY 2025: ₹29 Cr · +36.2% YoY28.8+36.2%FY 2025FY 2026: ₹57 Cr · +99.4% YoY57.5+99.4%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100150Q1'25: ₹82 Cr · -6.4% YoY82.3-6.4%Q1'25Q2'25: ₹84 Cr · +18.8% YoY83.7+18.8%Q2'25Q3'25: ₹63 Cr · -5.6% YoY63.2-5.6%Q3'25Q4'25: ₹82 Cr · +3.4% YoY81.9+3.4%Q4'25Q1'26: ₹84 Cr · +2.2% YoY84.1+2.2%Q1'26Q2'26: ₹71 Cr · -15.2% YoY71-15.2%Q2'26Q3'26: ₹77 Cr · +22.5% YoY77.4+22.5%Q3'26Q4'26: ₹100 Cr · +22.2% YoY100+22.2%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹332.6 Cr ₹311.1 Cr ₹304.55 Cr ₹266.09 Cr ₹235.01 Cr ₹214.33 Cr ₹183.27 Cr
Other Income ₹9.68 Cr ₹3.92 Cr ₹10.64 Cr ₹15.15 Cr ₹13.74 Cr ₹4.68 Cr ₹6.37 Cr
Total Income ₹342.28 Cr ₹315.03 Cr ₹315.18 Cr ₹281.24 Cr ₹248.75 Cr ₹219.02 Cr ₹189.63 Cr
Cost of Materials Consumed ₹70.62 Cr ₹63.95 Cr ₹54.31 Cr ₹52.99 Cr ₹60.65 Cr ₹38.66 Cr ₹29.36 Cr
Purchases of Stock-in-Trade ₹15.75 Cr ₹17.6 Cr ₹32.82 Cr ₹29.75 Cr ₹12.62 Cr ₹7.97 Cr ₹6.52 Cr
Changes in Inventories -₹4.41 Cr ₹6.78 Cr ₹8.74 Cr -₹5.25 Cr -₹10.56 Cr ₹3.6 Cr -₹16.17 Cr
Employee Benefit Expense ₹62.67 Cr ₹62.42 Cr ₹64.13 Cr ₹56.02 Cr ₹45.33 Cr ₹38.92 Cr ₹40.65 Cr
Finance Costs ₹10.93 Cr ₹12.7 Cr ₹19.78 Cr ₹9.32 Cr ₹4.06 Cr ₹6.6 Cr ₹7.37 Cr
Depreciation & Amortisation ₹18.88 Cr ₹16.8 Cr ₹17.17 Cr ₹20.7 Cr ₹16.58 Cr ₹13.31 Cr ₹13.07 Cr
Other Expenses ₹101.32 Cr ₹99.3 Cr ₹90.88 Cr ₹81.98 Cr ₹66.98 Cr ₹56.53 Cr ₹67.51 Cr
Total Expenses ₹275.76 Cr ₹279.56 Cr ₹287.84 Cr ₹245.5 Cr ₹195.67 Cr ₹165.59 Cr ₹148.31 Cr
Profit Before Exceptional Items & Tax ₹66.53 Cr ₹35.47 Cr ₹27.34 Cr ₹35.75 Cr ₹53.08 Cr ₹53.42 Cr ₹41.33 Cr
Exceptional Items ₹2.94 Cr ₹0 ₹0 ₹0 ₹0 -₹3.32 Cr ₹0
Profit Before Tax ₹69.46 Cr ₹35.47 Cr ₹27.34 Cr ₹35.75 Cr ₹53.08 Cr ₹50.1 Cr ₹41.33 Cr
Total Tax Expense ₹18.35 Cr ₹10.75 Cr ₹10.79 Cr ₹12.12 Cr ₹14.02 Cr ₹15.41 Cr ₹10.32 Cr
Net Profit ₹57.48 Cr ₹28.83 Cr ₹21.17 Cr ₹28.04 Cr ₹39.48 Cr ₹34.7 Cr ₹31 Cr
  attributable to Owners ₹55.64 Cr ₹27.49 Cr ₹18.89 Cr ₹26.63 Cr ₹39.32 Cr ₹34.43 Cr ₹29.17 Cr
  attributable to NCI ₹1.85 Cr ₹1.34 Cr ₹2.28 Cr ₹1.41 Cr ₹16.4 Lakh ₹26.8 Lakh ₹1.83 Cr
Other Comprehensive Income -₹2.33 Cr ₹5.9 Lakh -₹3.3 Lakh ₹1.63 Cr ₹82.1 Lakh -₹1.58 Cr ₹2.05 Cr
Total Comprehensive Income ₹55.16 Cr ₹28.89 Cr ₹21.13 Cr ₹29.66 Cr ₹40.31 Cr ₹33.12 Cr ₹33.05 Cr
EBITDA (computed) ₹96.34 Cr ₹64.98 Cr ₹64.29 Cr ₹65.76 Cr ₹73.72 Cr ₹73.34 Cr ₹61.77 Cr
Basic EPS ₹67.57 ₹33.89 ₹24.88 ₹32.96 ₹46.41 ₹40.79 ₹36.44
Diluted EPS ₹67.57 ₹33.89 ₹24.88 ₹0.00 ₹46.41 ₹40.79 ₹36.44
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹677.94 Cr ₹653.39 Cr ₹662.35 Cr ₹669.97 Cr
Non-current Assets ₹469.38 Cr ₹458.21 Cr ₹447.73 Cr ₹442.37 Cr
Current Assets ₹208.56 Cr ₹195.17 Cr ₹214.62 Cr ₹227.59 Cr
Property, Plant & Equipment ₹411.06 Cr ₹232.68 Cr ₹239.47 Cr ₹258.9 Cr
Inventories ₹72.53 Cr ₹70.38 Cr ₹75.58 Cr ₹84.81 Cr
Trade Receivables ₹95.36 Cr ₹73.18 Cr ₹78.65 Cr ₹79.63 Cr
Cash & Equivalents ₹2.77 Cr ₹5.59 Cr ₹12.75 Cr ₹13.16 Cr
Equity (Net Worth) ₹367.79 Cr ₹326.66 Cr ₹302.88 Cr ₹288.55 Cr
Equity Share Capital ₹8.51 Cr ₹8.51 Cr ₹8.51 Cr ₹8.51 Cr
Borrowings (Non-current) ₹89.96 Cr ₹133.37 Cr ₹181.77 Cr ₹184.85 Cr
Borrowings (Current) ₹98.29 Cr ₹74.41 Cr ₹57.27 Cr ₹83.3 Cr
Total Debt (computed) ₹188.26 Cr ₹207.78 Cr ₹239.04 Cr ₹268.15 Cr
Current Liabilities ₹152.48 Cr ₹125.18 Cr ₹105.79 Cr ₹148.7 Cr
Total Liabilities ₹310.15 Cr ₹326.73 Cr ₹359.47 Cr ₹381.42 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹64.14 Cr ₹64.51 Cr ₹48.13 Cr ₹23.6 Cr ₹8.81 Cr
Investing Cash Flow -₹3.29 Cr -₹19 Cr -₹22.65 Cr -₹77 Cr -₹116.59 Cr
Financing Cash Flow -₹48.79 Cr -₹51.72 Cr -₹26.05 Cr ₹41.76 Cr ₹111.61 Cr
Capital Expenditure ₹17.83 Cr ₹20.59 Cr ₹24.4 Cr ₹77.76 Cr ₹95.71 Cr
Free Cash Flow (computed) ₹46.31 Cr ₹43.92 Cr ₹23.74 Cr -₹54.17 Cr -₹86.9 Cr
Dividends Paid ₹6.03 Cr ₹5.17 Cr ₹6.81 Cr ₹8.51 Cr ₹8.51 Cr
Net Change in Cash -₹2.82 Cr -₹6.72 Cr -₹40.8 Lakh -₹11.59 Cr ₹3.48 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹100.11 Cr ₹77.42 Cr ₹70.97 Cr ₹84.11 Cr ₹81.93 Cr ₹63.22 Cr ₹83.69 Cr ₹82.27 Cr ₹79.26 Cr ₹66.98 Cr ₹70.46 Cr ₹87.85 Cr
Other Income -₹3.03 Cr ₹66.9 Lakh ₹9.73 Cr ₹2.32 Cr -₹6.95 Cr ₹7.81 Cr ₹1.84 Cr ₹1.23 Cr ₹4.15 Cr ₹99 Lakh ₹4.36 Cr ₹1.15 Cr
Total Income ₹97.08 Cr ₹78.08 Cr ₹80.7 Cr ₹86.42 Cr ₹74.98 Cr ₹71.03 Cr ₹85.53 Cr ₹83.49 Cr ₹83.4 Cr ₹67.97 Cr ₹74.81 Cr ₹89 Cr
Cost of Materials Consumed ₹21.3 Cr ₹18.34 Cr ₹17.43 Cr ₹13.56 Cr ₹15.56 Cr ₹16.53 Cr ₹15.91 Cr ₹15.95 Cr ₹14.47 Cr ₹13.34 Cr ₹14.29 Cr ₹12.22 Cr
Purchases of Stock-in-Trade ₹5.65 Cr ₹5.65 Cr -₹14.2 Lakh ₹4.59 Cr ₹4.7 Cr ₹4.79 Cr ₹3.02 Cr ₹5.09 Cr ₹6.41 Cr ₹5.96 Cr ₹6.02 Cr ₹14.43 Cr
Changes in Inventories -₹7.5 Cr -₹3.26 Cr ₹2.03 Cr ₹4.32 Cr ₹47.6 Lakh -₹1.69 Cr ₹5.6 Cr ₹2.4 Cr ₹66.3 Lakh ₹1.34 Cr -₹78.3 Lakh ₹7.52 Cr
Employee Benefit Expense ₹16.37 Cr ₹15.52 Cr ₹15.5 Cr ₹15.28 Cr ₹14.19 Cr ₹16.34 Cr ₹15.9 Cr ₹16 Cr ₹16.1 Cr ₹15.58 Cr ₹16.45 Cr ₹16 Cr
Finance Costs ₹5.1 Cr ₹1.82 Cr ₹2.21 Cr ₹1.81 Cr ₹5.62 Cr -₹3.81 Cr ₹5.89 Cr ₹5.01 Cr ₹6.94 Cr ₹2.19 Cr ₹8.08 Cr ₹2.57 Cr
Depreciation & Amortisation ₹5.91 Cr ₹4.43 Cr ₹4.35 Cr ₹4.18 Cr ₹4.18 Cr ₹4.29 Cr ₹4.2 Cr ₹4.13 Cr ₹3.74 Cr ₹3.75 Cr ₹4.28 Cr ₹5.4 Cr
Other Expenses ₹29.96 Cr ₹23.38 Cr ₹24.43 Cr ₹23.55 Cr ₹27.81 Cr ₹22.19 Cr ₹24.12 Cr ₹25.18 Cr ₹25.69 Cr ₹20.61 Cr ₹21.27 Cr ₹23.32 Cr
Total Expenses ₹76.79 Cr ₹65.88 Cr ₹65.81 Cr ₹67.28 Cr ₹72.54 Cr ₹58.64 Cr ₹74.62 Cr ₹73.76 Cr ₹74.01 Cr ₹62.77 Cr ₹69.6 Cr ₹81.46 Cr
Profit Before Exceptional Items & Tax ₹20.3 Cr ₹12.21 Cr ₹14.88 Cr ₹19.14 Cr ₹2.44 Cr ₹12.39 Cr ₹10.91 Cr ₹9.73 Cr ₹9.39 Cr ₹5.2 Cr ₹5.21 Cr ₹7.54 Cr
Exceptional Items ₹2.94 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹23.23 Cr ₹12.21 Cr ₹14.88 Cr ₹19.14 Cr ₹2.44 Cr ₹12.39 Cr ₹10.91 Cr ₹9.73 Cr ₹9.39 Cr ₹5.2 Cr ₹5.21 Cr ₹7.54 Cr
Total Tax Expense ₹8.54 Cr ₹4.21 Cr ₹2.71 Cr ₹2.89 Cr ₹2.2 Cr ₹1.96 Cr ₹3.48 Cr ₹3.11 Cr ₹3.47 Cr ₹2.39 Cr ₹2.72 Cr ₹2.2 Cr
Net Profit ₹16.55 Cr ₹9.31 Cr ₹14.33 Cr ₹17.3 Cr ₹1.54 Cr ₹11.41 Cr ₹8.39 Cr ₹7.49 Cr ₹6.4 Cr ₹4.02 Cr ₹4.04 Cr ₹6.71 Cr
  attributable to Owners ₹15.98 Cr ₹8.77 Cr ₹14.45 Cr ₹16.44 Cr ₹1.29 Cr ₹11.66 Cr ₹8.2 Cr ₹6.34 Cr ₹4.95 Cr ₹3.98 Cr ₹4.09 Cr ₹5.87 Cr
  attributable to NCI ₹56.4 Lakh ₹54.5 Lakh -₹11.8 Lakh ₹85.4 Lakh ₹25 Lakh -₹25.4 Lakh ₹19.2 Lakh ₹1.15 Cr ₹1.45 Cr ₹3.6 Lakh -₹4.5 Lakh ₹84.1 Lakh
Other Comprehensive Income -₹63.1 Lakh -₹40.5 Lakh -₹1.12 Cr -₹17.6 Lakh -₹17.2 Lakh -₹36.9 Lakh ₹20.9 Lakh ₹39.1 Lakh ₹1.15 Cr -₹23.2 Lakh -₹56.9 Lakh -₹38.4 Lakh
Total Comprehensive Income ₹15.92 Cr ₹8.91 Cr ₹13.22 Cr ₹17.12 Cr ₹1.37 Cr ₹11.04 Cr ₹8.6 Cr ₹7.88 Cr ₹7.55 Cr ₹3.79 Cr ₹3.47 Cr ₹6.33 Cr
EBITDA (computed) ₹31.3 Cr ₹18.46 Cr ₹21.45 Cr ₹25.13 Cr ₹12.23 Cr ₹12.87 Cr ₹21 Cr ₹18.88 Cr ₹20.07 Cr ₹11.15 Cr ₹17.57 Cr ₹15.51 Cr
Basic EPS ₹19.45 ₹10.94 ₹16.85 ₹20.33 ₹1.82 ₹13.41 ₹9.86 ₹8.80 ₹7.52 ₹4.73 ₹4.75 ₹7.89
Diluted EPS ₹19.45 ₹10.94 ₹16.85 ₹20.33 ₹1.82 ₹13.41 ₹9.86 ₹8.80 ₹7.52 ₹4.73 ₹4.75 ₹7.89
Latest 12 quarters shown of 24 on record.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Poultry Healthcare ₹64.72 Cr ₹23.11 Cr ₹123.36 Cr ₹15.8 Cr
Animal Healthcare ₹35.39 Cr ₹4.95 Cr ₹225.39 Cr ₹23.32 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Poultry Healthcare ₹205.97 Cr ₹58.09 Cr - -
Animal Healthcare ₹126.63 Cr ₹25.27 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹292.14 Cr ₹286.47 Cr ₹285.16 Cr ₹254 Cr ₹219.35 Cr ₹208.48 Cr ₹169.43 Cr
Other Income ₹7.64 Cr ₹4.76 Cr ₹4.26 Cr ₹5.32 Cr ₹4.66 Cr ₹1.65 Cr ₹2.93 Cr
Total Income ₹299.77 Cr ₹291.23 Cr ₹289.42 Cr ₹259.32 Cr ₹224.01 Cr ₹210.13 Cr ₹172.35 Cr
Cost of Materials Consumed ₹46.22 Cr ₹38.86 Cr ₹32.69 Cr ₹29.28 Cr ₹34.93 Cr ₹24.18 Cr ₹21.13 Cr
Purchases of Stock-in-Trade ₹39.44 Cr ₹44.84 Cr ₹56.6 Cr ₹55.37 Cr ₹39.3 Cr ₹25.21 Cr ₹17.19 Cr
Changes in Inventories -₹3.69 Cr ₹9.97 Cr ₹10.36 Cr -₹4.77 Cr -₹12.53 Cr ₹4.01 Cr -₹15.57 Cr
Employee Benefit Expense ₹53.17 Cr ₹54.76 Cr ₹56.72 Cr ₹47.92 Cr ₹39.12 Cr ₹33.45 Cr ₹37.16 Cr
Finance Costs ₹7.17 Cr ₹5.37 Cr ₹5.09 Cr ₹6.5 Cr ₹2.47 Cr ₹3.95 Cr ₹5.03 Cr
Depreciation & Amortisation ₹10.25 Cr ₹8.58 Cr ₹9.78 Cr ₹9.79 Cr ₹9.5 Cr ₹9.63 Cr ₹9.39 Cr
Other Expenses ₹84.52 Cr ₹87.1 Cr ₹81.45 Cr ₹71.32 Cr ₹57.96 Cr ₹49.64 Cr ₹56.8 Cr
Total Expenses ₹237.09 Cr ₹249.47 Cr ₹252.69 Cr ₹215.4 Cr ₹170.75 Cr ₹150.06 Cr ₹131.12 Cr
Profit Before Exceptional Items & Tax ₹62.69 Cr ₹41.76 Cr ₹36.73 Cr ₹43.92 Cr ₹53.26 Cr ₹60.06 Cr ₹41.23 Cr
Exceptional Items ₹7 Cr ₹0 ₹0 ₹0 ₹0 -₹5.28 Cr ₹0
Profit Before Tax ₹69.68 Cr ₹41.76 Cr ₹36.73 Cr ₹43.92 Cr ₹53.26 Cr ₹54.78 Cr ₹41.23 Cr
Total Tax Expense ₹17.58 Cr ₹9.92 Cr ₹9.57 Cr ₹11.58 Cr ₹13.74 Cr ₹14.88 Cr ₹10 Cr
Net Profit ₹52.1 Cr ₹31.84 Cr ₹27.16 Cr ₹32.34 Cr ₹39.52 Cr ₹39.9 Cr ₹31.22 Cr
Other Comprehensive Income -₹5 Lakh -₹36.3 Lakh -₹2.4 Lakh ₹11.3 Lakh -₹15.7 Lakh ₹21.4 Lakh -₹40.1 Lakh
Total Comprehensive Income ₹52.05 Cr ₹31.48 Cr ₹27.14 Cr ₹32.46 Cr ₹39.36 Cr ₹40.12 Cr ₹30.82 Cr
EBITDA (computed) ₹80.11 Cr ₹55.71 Cr ₹51.6 Cr ₹60.21 Cr ₹65.23 Cr ₹73.64 Cr ₹55.65 Cr
Basic EPS ₹61.24 ₹37.43 ₹31.93 ₹38.02 ₹46.45 ₹46.90 ₹36.70
Diluted EPS ₹61.24 ₹37.43 ₹31.93 ₹38.02 ₹46.45 ₹46.90 ₹36.70
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹557.35 Cr ₹546 Cr ₹549.55 Cr ₹545.82 Cr
Non-current Assets ₹367.58 Cr ₹360.76 Cr ₹345.13 Cr ₹329.77 Cr
Current Assets ₹189.76 Cr ₹185.24 Cr ₹204.41 Cr ₹216.05 Cr
Property, Plant & Equipment ₹287.61 Cr ₹104.83 Cr ₹102.89 Cr ₹107.85 Cr
Inventories ₹59.98 Cr ₹58.51 Cr ₹68.53 Cr ₹79.22 Cr
Trade Receivables ₹92.04 Cr ₹80.6 Cr ₹85.78 Cr ₹82.36 Cr
Cash & Equivalents ₹79 Lakh ₹54.5 Lakh ₹2.41 Cr ₹4.3 Cr
Equity (Net Worth) ₹385.18 Cr ₹339.09 Cr ₹312.71 Cr ₹292.38 Cr
Equity Share Capital ₹8.51 Cr ₹8.51 Cr ₹8.51 Cr ₹8.51 Cr
Borrowings (Non-current) ₹21.68 Cr ₹51.31 Cr ₹79.07 Cr ₹83.4 Cr
Borrowings (Current) ₹52.79 Cr ₹52.96 Cr ₹54.49 Cr ₹80.93 Cr
Total Debt (computed) ₹74.47 Cr ₹104.27 Cr ₹133.56 Cr ₹164.32 Cr
Current Liabilities ₹91.92 Cr ₹96.7 Cr ₹97.72 Cr ₹136.47 Cr
Total Liabilities ₹172.16 Cr ₹206.91 Cr ₹236.83 Cr ₹253.43 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹50.92 Cr ₹63.97 Cr ₹42.81 Cr ₹33.36 Cr ₹15.91 Cr
Investing Cash Flow -₹2.36 Cr -₹19.04 Cr -₹20.63 Cr -₹71.96 Cr -₹110.58 Cr
Financing Cash Flow -₹48.31 Cr -₹46.35 Cr -₹24.07 Cr ₹41.38 Cr ₹94.96 Cr
Capital Expenditure ₹17.33 Cr ₹20.63 Cr ₹22.38 Cr ₹72.64 Cr ₹90.67 Cr
Free Cash Flow (computed) ₹33.6 Cr ₹43.34 Cr ₹20.44 Cr -₹39.28 Cr -₹74.76 Cr
Dividends Paid ₹6.03 Cr ₹5.17 Cr ₹6.81 Cr ₹8.51 Cr ₹8.51 Cr
Net Change in Cash ₹24.5 Lakh -₹1.42 Cr -₹1.89 Cr ₹2.77 Cr ₹28.4 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹93.71 Cr ₹70.35 Cr ₹64.58 Cr ₹63.49 Cr ₹76.67 Cr ₹62.83 Cr ₹73.5 Cr ₹73.47 Cr ₹72.87 Cr ₹65.51 Cr ₹66.43 Cr ₹80.35 Cr
Other Income ₹4.18 Cr ₹1.04 Cr ₹1.48 Cr ₹94.6 Lakh ₹1.06 Cr ₹1.3 Cr ₹1.35 Cr ₹1.06 Cr ₹1.2 Cr ₹98 Lakh ₹1.22 Cr ₹85.9 Lakh
Total Income ₹97.89 Cr ₹71.39 Cr ₹66.05 Cr ₹64.44 Cr ₹77.73 Cr ₹64.13 Cr ₹74.85 Cr ₹74.52 Cr ₹74.08 Cr ₹66.49 Cr ₹67.65 Cr ₹81.2 Cr
Cost of Materials Consumed ₹16.51 Cr ₹11.31 Cr ₹9.72 Cr ₹8.68 Cr ₹9.02 Cr ₹8.44 Cr ₹10.81 Cr ₹10.59 Cr ₹9.17 Cr ₹6.65 Cr ₹8.43 Cr ₹8.43 Cr
Purchases of Stock-in-Trade ₹9.83 Cr ₹12.84 Cr ₹7.84 Cr ₹8.93 Cr ₹13.64 Cr ₹12.01 Cr ₹9.26 Cr ₹9.93 Cr ₹13.59 Cr ₹13.57 Cr ₹11.68 Cr ₹17.75 Cr
Changes in Inventories -₹6 Cr -₹2.78 Cr ₹3.21 Cr ₹1.87 Cr ₹3.28 Cr -₹27.2 Lakh ₹4.52 Cr ₹2.44 Cr ₹51.4 Lakh ₹1.43 Cr ₹25.8 Lakh ₹8.16 Cr
Employee Benefit Expense ₹14 Cr ₹12.91 Cr ₹13.02 Cr ₹13.25 Cr ₹12.14 Cr ₹14.31 Cr ₹14.11 Cr ₹14.21 Cr ₹14.32 Cr ₹13.61 Cr ₹14.66 Cr ₹14.13 Cr
Finance Costs ₹4.09 Cr ₹89.8 Lakh ₹1.27 Cr ₹90.5 Lakh ₹1.25 Cr ₹1.59 Cr ₹1.4 Cr ₹1.13 Cr ₹1.31 Cr ₹1.37 Cr ₹1.48 Cr ₹94.2 Lakh
Depreciation & Amortisation ₹3.68 Cr ₹2.21 Cr ₹2.2 Cr ₹2.16 Cr ₹2.03 Cr ₹2.24 Cr ₹2.19 Cr ₹2.12 Cr ₹2.08 Cr ₹2.57 Cr ₹2.58 Cr ₹2.55 Cr
Other Expenses ₹27.9 Cr ₹19.35 Cr ₹18.92 Cr ₹18.35 Cr ₹24.89 Cr ₹19.32 Cr ₹20.08 Cr ₹22.81 Cr ₹22.86 Cr ₹18.67 Cr ₹19.41 Cr ₹20.51 Cr
Total Expenses ₹70.02 Cr ₹56.75 Cr ₹56.17 Cr ₹54.15 Cr ₹66.25 Cr ₹57.64 Cr ₹62.37 Cr ₹63.22 Cr ₹63.85 Cr ₹57.87 Cr ₹58.49 Cr ₹72.47 Cr
Profit Before Exceptional Items & Tax ₹27.87 Cr ₹14.64 Cr ₹9.88 Cr ₹10.29 Cr ₹11.48 Cr ₹6.49 Cr ₹12.48 Cr ₹11.31 Cr ₹10.23 Cr ₹8.61 Cr ₹9.16 Cr ₹8.73 Cr
Exceptional Items ₹7 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹34.87 Cr ₹14.64 Cr ₹9.88 Cr ₹10.29 Cr ₹11.48 Cr ₹6.49 Cr ₹12.48 Cr ₹11.31 Cr ₹10.23 Cr ₹8.61 Cr ₹9.16 Cr ₹8.73 Cr
Total Tax Expense ₹8.49 Cr ₹3.97 Cr ₹2.67 Cr ₹2.45 Cr ₹1.85 Cr ₹2.05 Cr ₹3.15 Cr ₹2.87 Cr ₹2.79 Cr ₹2.14 Cr ₹2.38 Cr ₹2.26 Cr
Net Profit ₹26.38 Cr ₹10.67 Cr ₹7.21 Cr ₹7.84 Cr ₹9.64 Cr ₹4.44 Cr ₹9.34 Cr ₹8.43 Cr ₹7.43 Cr ₹6.48 Cr ₹6.78 Cr ₹6.47 Cr
Other Comprehensive Income -₹5 Lakh ₹18.2 Lakh -₹9.2 Lakh -₹9 Lakh -₹34.5 Lakh -₹60,000 -₹60,000 -₹60,000 -₹10.9 Lakh ₹2.9 Lakh ₹2.7 Lakh ₹2.9 Lakh
Total Comprehensive Income ₹26.33 Cr ₹10.85 Cr ₹7.12 Cr ₹7.75 Cr ₹9.29 Cr ₹4.43 Cr ₹9.33 Cr ₹8.43 Cr ₹7.32 Cr ₹6.5 Cr ₹6.81 Cr ₹6.5 Cr
EBITDA (computed) ₹35.64 Cr ₹17.75 Cr ₹13.36 Cr ₹13.36 Cr ₹14.76 Cr ₹10.32 Cr ₹16.08 Cr ₹14.55 Cr ₹13.62 Cr ₹12.55 Cr ₹13.21 Cr ₹12.22 Cr
Basic EPS ₹31.01 ₹12.54 ₹8.48 ₹9.21 ₹11.33 ₹5.22 ₹10.97 ₹9.91 ₹8.74 ₹7.61 ₹7.97 ₹7.61
Diluted EPS ₹31.01 ₹12.54 ₹8.48 ₹9.21 ₹11.33 ₹5.22 ₹10.97 ₹9.91 ₹8.74 ₹7.61 ₹7.97 ₹7.61
Latest 12 quarters shown of 24 on record.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Poultry Healthcare ₹65.07 Cr ₹23.52 Cr ₹122.99 Cr ₹15.67 Cr
Animal Healthcare ₹28.64 Cr ₹10.2 Cr ₹67.98 Cr ₹10.05 Cr
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Poultry Healthcare ₹206.13 Cr ₹58.14 Cr - -
Animal Healthcare ₹86.01 Cr ₹16.39 Cr - -
Want more history and ratios?
You're viewing the latest exchange-filed financials for Hester Biosciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Hester Biosciences Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 53.73%, foreign institutional investors hold 0.38%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 45.89% of Hester Biosciences Limited. The company had 12,373 shareholders on record.

Promoters: 53.73%FII (Foreign Institutional): 0.38%Retail & Others: 45.89%
Mar 2026
QUARTER
53.73% Promoters
0.38% FII (Foreign Institutional)
45.89% Retail & Others
Promoter holding - history
Now 53.73% · Mar 2026High 54.09% · Mar 2018Low 53.73% · Dec 2019
52%53%54%55%56%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 54.07%Mar 2016: 54.07%Jun 2016: 54.07%Sep 2016: 54.07%Dec 2016: 54.07%Mar 2017: 54.07%Jun 2017: 54.07%Sep 2017: 54.08%Dec 2017: 54.08%Mar 2018: 54.09%Jun 2018: 54.09%Sep 2018: 54.09%Dec 2018: 54.09%Mar 2019: 54.09%Jun 2019: 54.09%Sep 2019: 53.74%Dec 2019: 53.73%Mar 2020: 53.73%Jun 2020: 53.73%Sep 2020: 53.73%Dec 2020: 53.73%Mar 2021: 53.73%Jun 2021: 53.73%Sep 2021: 53.73%Dec 2021: 53.73%Mar 2022: 53.73%Jun 2022: 53.73%Sep 2022: 53.73%Dec 2022: 53.73%Mar 2023: 53.73%Jun 2023: 53.73%Sep 2023: 53.73%Dec 2023: 53.73%Mar 2024: 53.73%Jun 2024: 53.73%Sep 2024: 53.73%Dec 2024: 53.73%Mar 2025: 53.73%Jun 2025: 53.73%Sep 2025: 53.73%Dec 2025: 53.73%Mar 2026: 53.73%54.09%53.73%53.73%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters53.73%53.73%53.73%53.73%53.73%53.73%
Public46.27%46.27%46.27%46.27%46.27%46.27%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters53.73%53.73%53.73%53.73%53.73%53.73%53.73%54.09%54.09%54.07%54.07%
Public46.27%46.27%46.27%46.27%46.27%46.27%46.27%45.91%45.91%45.93%45.93%
Promoter change (YoY, %pts)+0.00+0.00+0.00+0.00+0.00+0.00-0.36+0.00+0.02+0.00-

Board & Governance of Hester Biosciences Limited

As per the corporate governance filing with NSE for the quarter ended 31-DEC-2025, the board of Hester Biosciences Limited has 11 directors - 5 independent and 2 executive. The board is chaired by Bhupendra Vittaldas Gandhi.

DirectorPositionOn board sinceListed boards
Bhupendra Vittaldas Gandhi Non-Executive - Non Independent Director · Chairperson 2005-04-21 1
Rajiv Dinesh Gandhi Executive Director · CEO-MD 1987-04-29 2
Sanjiv Dinesh Gandhi Non-Executive - Non Independent Director 1987-04-29 1
Ravin Kanti Gandhi Non-Executive - Non Independent Director 1999-04-22 1
Nina Rajiv Gandhi Alternate Director 2016-05-07 1
Priya Gandhi Executive Director 2021-10-28 1
Sandhya Maulik Patel Non-Executive - Independent Director · Shareholder Director 2020-04-01 1
Ashok Bhhimarao Bhadakal Non-Executive - Independent Director · Shareholder Director 2020-04-01 1
Ameet Hiranyakumar Desai Non-Executive - Independent Director · Shareholder Director 2021-10-28 4
Jatin Trivedi Non-Executive - Independent Director · Shareholder Director 2023-06-26 1
Anil Jain Non-Executive - Independent Director · Shareholder Director 2023-06-26 2
Board Committees
CommitteeMembers
Audit Committee Ashok Bhadakal (Chairperson), Sandhya Patel, Priya Gandhi
Nomination and remuneration committee Ashok Bhadakal (Chairperson), Sandhya Patel, Sanjiv Gandhi
Stakeholders Relationship Committee Sandhya Patel (Chairperson), Rajiv Gandhi, Priya Gandhi
Risk Management Committee Rajiv Gandhi (Chairperson), Sandhya Patel, Priya Gandhi
Corporate Social Responsibility Committee Rajiv Gandhi (Chairperson), Sanjiv Gandhi, Sandhya Patel

Group Structure of Hester Biosciences Limited

Hester Biosciences Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Hester Biosciences Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Texas Lifesciences Private Limited U24304GJ2017PTC097758 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Hester Biosciences Limited

Open charges
₹202.05 Cr
Satisfied charges
₹90.09 Cr
Breakdown by lending institutions
State Bank of India₹202.05 Cr
Latest charge details
DateLenderAmountStatus
18 Dec 2021 State Bank of India ₹91.08 Cr Open
28 Dec 2013 State Bank of India ₹110.97 Cr Open
15 Apr 2020 State Bank of India ₹5 Cr Satisfied
16 Oct 2019 Hdfc Bank Limited ₹37.7 Lakh Satisfied
26 Jul 2019 Axis Bank Limited ₹55.27 Lakh Satisfied

Total charge records: 30 View all charges

Employees and EPFO Compliance at Hester Biosciences Limited

Hester Biosciences Limited has a workforce of 695 employees as of Sep 23, 2025.

Employee count
695
Active EPFO establishments
1
Employee growth
1.31%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Hester Biosciences Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Hester Biosciences Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Hester Biosciences Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Hester Biosciences Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Hester Biosciences Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Hester Biosciences Limited

MSME Payment Delays by Hester Biosciences Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Hester Biosciences Limited

Subsidiaries & Group Companies of Hester Biosciences Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Hester Biosciences Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Hester Biosciences Limited

MCA Filings & Documents of Hester Biosciences Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Hester Biosciences Limited

Directors
20 Nov 2025
Ashish Dinesh Desai was appointed as a Cfo on 20 Nov 2025 & has been associated with this company since 7 months 19 days.
Activity
13 Aug 2025
Hester Biosciences Limited last Annual general meeting of members was held on 13 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Hester Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Charges
11 Jul 2024
A charge registered on 26 Jul 2019 via Charge ID 100280285 with Axis Bank Limited was fully satisfied on 11 Jul 2024.
Directors
26 Jun 2023
Jatin Yagneshbhai Trivedi was appointed as a Director on 26 Jun 2023 & has been associated with this company since 3 years 14 days.
Directors
26 Jun 2023
Anilkumar Mithalal Jain was appointed as a Director on 26 Jun 2023 & has been associated with this company since 3 years 14 days.

Recent News on Hester Biosciences Limited

Stocks that will see action today January 30, 2025
30 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Hester Biosciences Limited

Hester Biosciences Limited is an active public limited company in the pharma sector based in Mahesana, Gujarat, India. It was incorporated on 29 April 1987 (39+ years old) and is registered under CIN L99999GJ1987PLC022333. Listed on BSE: 524669 and NSE: HESTERBIO. The company has 695 employees.

Hester Biosciences Limited reported revenue of ₹315.03 Cr for FY 2025 (up 0.00% YoY).

The current directors of Hester Biosciences Limited are:

The primary industry of Hester Biosciences Limited is pharma. The company specifically operates in animal pharmaceuticals and healthcare. The company is currently active in this sector.

Yes. Hester Biosciences Limited is listed on both BSE (code: 524669) and NSE (symbol: HESTERBIO).

Hester Biosciences Limited can be reached at the registered office: Village Meda – Adraj, Taluka Kadi, Mahesana, Gujarat, India – 384441, or through the website hester.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available